Display options
Cite
Gholijani N, Gharagozloo M, Kalantar F, et al. Modulation of Cytokine Production and Transcription Factors Activities in Human Jurkat T Cells by Thymol and Carvacrol. Adv Pharm Bull. 2015;5:653-60doi: 10.15171/apb.2015.089.
Gholijani, N., Gharagozloo, M., Kalantar, F., Ramezani, A., & Amirghofran, Z. (2015). Modulation of Cytokine Production and Transcription Factors Activities in Human Jurkat T Cells by Thymol and Carvacrol. Advanced pharmaceutical bulletin, 5653-60. https://doi.org/10.15171/apb.2015.089
Gholijani, Nasser, et al. "Modulation of Cytokine Production and Transcription Factors Activities in Human Jurkat T Cells by Thymol and Carvacrol." Advanced pharmaceutical bulletin vol. 5 (2015): 653-60. doi: https://doi.org/10.15171/apb.2015.089
Gholijani N, Gharagozloo M, Kalantar F, Ramezani A, Amirghofran Z. Modulation of Cytokine Production and Transcription Factors Activities in Human Jurkat T Cells by Thymol and Carvacrol. Adv Pharm Bull. 2015 Dec;5:653-60. doi: 10.15171/apb.2015.089. Epub 2015 Dec 31. PMID: 26793612; PMCID: PMC4708037.
Copy Download .nbib Format: NLM
Share it on

Adv Pharm Bull. 2015 Dec;5:653-60. doi: 10.15171/apb.2015.089. Epub 2015 Dec 31.

Modulation of Cytokine Production and Transcription Factors Activities in Human Jurkat T Cells by Thymol and Carvacrol.

Advanced pharmaceutical bulletin

Nasser Gholijani, Marjan Gharagozloo, Fathollah Kalantar, Amin Ramezani, Zahra Amirghofran

Affiliations

  1. Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  2. Department of Immunology, Isfahan University of Medical Sciences, Isfahan, Iran. ; Department of Pediatrics, CR-CHUS, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke,Quebec,Canada.
  3. Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran.
  4. Department of Medical Biotechnology, School of Advanced Medical Sciences and Technology, Shiraz University of Medical Sciences, Shiraz, Iran. ; Institute for Cancer Research, Shiraz University of Medical sciences, Shiraz, Iran.
  5. Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran. ; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

PMID: 26793612 PMCID: PMC4708037 DOI: 10.15171/apb.2015.089

Abstract

PURPOSE: Thymol and carvacrol, two main components of thyme, have shown anti-inflammatory effects. The aim of this study was to assess the effects of these components on Jurkat leukemia cells as an in vitro T cell model and their molecular mechanisms of activity.

METHODS: Cells were cultured in the presence of components and subsequently stimulated with phorbol-12-myristate-13-acetate (PMA)/calcium ionophore for evaluating interleukin (IL)-2 and interferon (IFN)-γ production. The activation of T cell transcription factors that included nuclear factors of activated T cells (NFATs), activator protein-1 (AP-1; c-Jun/c-Fos), and nuclear factor (NF)-κB were examined by Western blot analysis.

RESULTS: Thymol and carvacrol at 25 µg/ml significantly reduced IL-2 levels from 119.4 ± 8pg/ml in control cells treated only with PMA/Calcium ionophore and the solvent to 66.9 ± 6.4pg/ml (thymol) and 32.3 ± 3.6pg/ml (carvacrol) and IFN-γ from 423.7 ± 19.7pg/ml in control cells to 311.9 ± 11.6pg/ml (thymol) and 293.5 ± 16.7pg/ml (carvacrol). Western blot analyses of nuclear extracts showed that the same concentrations of components significantly reduced NFAT-2 to 44.2 ± 2.7% (thymol) and 91.4 ± 2.3% (carvacrol) of the control (p<0.05), and c-Fos to 31.2 ± 6.2% (thymol) and 27.6 ± 3.1% (carvacrol) of the control (p<0.01). No effects on NFAT-1, c-Jun and phospho-NF-κBp65 levels were observed.

CONCLUSION: Thymol and carvacrol could contribute to modulation of T cell activity by reducing IL-2 and IFN-γ production possibly through down regulation of AP-1 and NFAT-2 transcription factors suggesting their potential usefulness for reduction of T cell overactivity in immune-mediated diseases.

Keywords: Carvacrol; Jurkat cells; Thymol; Transcription factors

References

  1. Iran J Allergy Asthma Immunol. 2012 Jun;11(2):111-9 - PubMed
  2. Immunol Invest. 2009;38(2):181-92 - PubMed
  3. Annu Rev Immunol. 1997;15:707-47 - PubMed
  4. J Immunol. 2000 Jul 15;165(2):860-8 - PubMed
  5. Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):253-63 - PubMed
  6. Immunol Rev. 2006 Apr;210:171-86 - PubMed
  7. J Ethnopharmacol. 2000 Sep;72(1-2):167-72 - PubMed
  8. Immunol Rev. 2010 Nov;238(1):247-62 - PubMed
  9. Front Immunol. 2012 Dec 14;3:379 - PubMed
  10. J Ethnopharmacol. 2015 Feb 3;160:94-100 - PubMed
  11. Cytotechnology. 2012 Jan;64(1):43-51 - PubMed
  12. J Immunoassay Immunochem. 2012;33(4):388-402 - PubMed
  13. EMBO J. 1993 Oct;12(10):3879-91 - PubMed
  14. Mol Cell Biol. 1999 Mar;19(3):2300-7 - PubMed
  15. Eur J Pharmacol. 2014 Jan 15;723:91-8 - PubMed
  16. Immunity. 2015 Feb 17;42(2):265-78 - PubMed
  17. Cell Mol Immunol. 2008 Feb;5(1):23-31 - PubMed
  18. Phytother Res. 2008 Sep;22(9):1154-8 - PubMed
  19. J Immunotoxicol. 2016;13(2):157-64 - PubMed
  20. Clin Dev Immunol. 2012;2012:925135 - PubMed
  21. J Immunotoxicol. 2011 Oct-Dec;8(4):265-73 - PubMed
  22. EMBO J. 2000 Sep 1;19(17):4783-95 - PubMed
  23. Genes Dev. 1989 Dec;3(12B):2091-100 - PubMed
  24. J Appl Oral Sci. 2014 Jun;22(3):185-93 - PubMed
  25. J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73 - PubMed
  26. Braz J Med Biol Res. 2005 Mar;38(3):335-44 - PubMed
  27. Inflammation. 2014 Feb;37(1):214-22 - PubMed
  28. Planta Med. 2005 Jul;71(7):634-9 - PubMed
  29. Pharm Biol. 2016 Jul;54(7):1125-32 - PubMed

Publication Types